NOV 15, 2017 10:00 AM PST

WEBINAR: Characterization of immune checkpoint expression & infiltrating immune cells in TME by RNAscope ISH

Speakers
  • Scientist, Advanced Cell Diagnostics
    Biography
      Currently I am a scientist in R&D at Advanced Cell Diagnostics (ACD) in Newark, California. In the applications group we manage numerous projects within the ACD R&D laboratories and with collaborators from around the globe to demonstrate new and exciting applications of the RNAscope and BaseScope technologies and their ability to detect RNA biomarkers with single-molecule sensitivity and single-cell resolution within the morphological context.

      Prior to joining ACD, I completed my postdoctoral studies in cancer biology at the University of California San Francisco. I received my Ph.D. in cognitive and molecular neurosciences from the University of Leuven (Belgium) after completing a one-year visiting scientist position focusing on medical entomology at the University of Florida. Prior, I graduated as bio-engineer in cell-and gene biotechnology from the University of Leuven with a 6-month international exchange program at the University of Milan (Italy).

    Abstract:

    DATE: November 15, 2017
    TIME: 10:00AM PT

    Interactions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with accumulating evidence indicating a crucial role for tumor infiltrating immune cells. Although infiltrating T cells have been correlated with improved clinical outcome, they are ineffective in eradicating tumors due to their inhibition by immune checkpoint molecules. 


    Immune checkpoint inhibitors have demonstrated therapeutic efficacy and durable response for several tumor types, including NSCLC. However, the majority of patients are resistant or relapse after initial response. Characterizing the TME for checkpoint expression with single-cell and spatial resolution can provide critical insight into new immunotherapeutic strategies and identify new predictive biomarkers for stratifying patients most likely to benefit from immunotherapies. 


    In addition, the visualization of immunosuppressive factors that contribute to tumor evasion by recruiting and modulating regulatory T cells and myeloid-derived cells could offer a more comprehensive understanding of the TME.
    In this webinar, we will highlight the in situ visualization of the following targets at the single-cell level in the TME of NSCLC and ovarian cancer archived FFPE tissue samples using the highly specific and sensitive in situ hybridization assay RNAscope®: - Expression and co-expression profiles of therapeutic checkpoint targets including PD1, PD-L1, PD-L2, TIM3, LAG3, CTLA-4 and GITR in individual infiltrating immune cells within the morphological tissue context.
    - Immune infiltration and state of lymphoid and myeloid cells in the TME by detecting key functional molecules, FOXP3, IFNg, CXCL10, and CCL22 combined with cell lineage markers CD4, CD8, CD68, and CD163.

     


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 24, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    MAY 29, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 29, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    Loading Comments...